Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 22:2022:6094409.
doi: 10.1155/2022/6094409. eCollection 2022.

Diagnostic Value of Prostate-Specific Antigen Combined with Plasma miRNA-149 Expression in Patients with Prostate Cancer Based on Experimental Data and Bioinformatics

Hao Wang  1 , Ling Yang  1 , Ying Mi  1 , Yanan Wang  1 , Chunmei Ma  1 , Jing Zhao  1 , Ping Liu  1 , Yu Gao  1 , Peijun Li  1
Affiliations

Diagnostic Value of Prostate-Specific Antigen Combined with Plasma miRNA-149 Expression in Patients with Prostate Cancer Based on Experimental Data and Bioinformatics

Hao Wang et al. Contrast Media Mol Imaging. .

Abstract

Purpose: The aim of this study is to explore the diagnostic value of prostate-specific antigen (PSA) combined with serum miRNA-149 expression in prostate cancer (PCa) by conducting experiments and bioinformatics analysis. Patients and Methods. 50 PCa patients were enrolled on the experimental group from January 2020 to December 2021. 56 patients with benign prostatic hyperplasia (BPH) were selected as the control group at the same time. Real-time fluorescent quantitative PCR was applied to investigate the miRNA-149 expression. PSA was detected by using a chemiluminescence meter using Abbott i4000. Applying bioinformatics analysis, we explored the expression of hsa-miR-149 in PCa in The Cancer Genome Atlas (TCGA) database. Kaplan-Meier analyses were used to evaluate the prognostic value, and the ROC curve was applied.

Results: The expression level of miRNA-149 in the PCa group was significantly higher than that in the BPH group (P < 0.05). The PSA level in the PCa group was also significantly higher than that in the BPH group (P < 0.05). TCGA data analysis revealed that PCa tissues had significantly increased hsa-miR-149 expression. The results of survival analysis showed that patients with high expression of hsa-miR-149 had better prognosis. Additionally, the pathological N stage of PCa correlates with the hsa-miR-149 expression level (P = 0.002). According to ROC curve analysis, the region under the curve was 0.653, 95% CI: 0.576-0.730.

Conclusion: High expression of serum miRNA-149 is associated with PCa patients. Although combined PSA did not improve the diagnostic efficacy, miRNA-149 has high specificity in the diagnosis of PCa. miRNA-149 might be a novel marker for early diagnosis and prognosis assessment for PCa.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Expression level of miRNA-149 in both PCa group and BPH group. BPH, benign prostatic hyperplasia; PCa, prostate cancer.
Figure 2
Figure 2
Expression level of PSA in both PCa group and BPH group. BPH, benign prostatic hyperplasia; PSA, prostate-specific antigen; PCa, prostate cancer.
Figure 3
Figure 3
The relative expression of hsa-miR-149 in the TCGA dataset.
Figure 4
Figure 4
Kaplan–Meier analysis of overall survival according to high or low hsa-miR-149 expression in the TCGA database.
Figure 5
Figure 5
The relative expression of hsa-miR-149 across different pathological stages.
Figure 6
Figure 6
The ROC curve of hsa-miR-149 in the TCGA dataset.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Litwin M. S., Tan H. J. The diagnosis and treatment of prostate cancer: a review. JAMA . 2017;317(24):p. 2532. doi: 10.1001/jama.2017.7248. - DOI - PubMed
    1. Liu X., Yu C., Bi Y., Zhang Z. J. Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China. Public Health . 2019;172:70–80. doi: 10.1016/j.puhe.2019.04.016. - DOI - PubMed
    1. Fu Z. T., Guo X. L., Zhang S. W., et al. [Statistical analysis of incidence and mortality of prostate cancer in China, 2015] Zhonghua Zhongliu Zazhi . 2020;42(9):718–722. doi: 10.3760/cma.j.cn112152-20200313-00200. - DOI - PubMed
    1. Terada N., Akamatsu S., Kobayashi T., Inoue T., Ogawa O., Antonarakis E. S. Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. Ther Adv Med Oncol . 2017;9(8):565–573. doi: 10.1177/1758834017719215. - DOI - PMC - PubMed
    1. Chen R., Sjoberg D. D., Huang Y., et al. Prostate specific antigen and prostate cancer in Chinese men undergoing initial prostate biopsies compared with western cohorts. The Journal of Urology . 2017;197(1):90–96. doi: 10.1016/j.juro.2016.08.103. - DOI - PMC - PubMed